{"entity":{"id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of OTP-01 in advanced solid tumours, run by Ottimo Pharma Limited, now recruiting.","summary":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07266428 by Ottimo Pharma Limited, with 170 participants planned, started 2025-12-17 and due to reach its primary completion in 2028-12. Interventions recorded: OTP-01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07266428","url":"https://clinicaltrials.gov/study/NCT07266428"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07266428","phase":"1/2","setting":"Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","sponsor":"Ottimo Pharma Limited","enrolled":170,"outcomes":[]},"route":"/trials/nct07266428/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}